vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $183.1M, roughly 1.0× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 0.9%, a 12.4% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $16.0M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
AMPH vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $185.2M |
| Net Profit | $24.4M | $1.7M |
| Gross Margin | 46.8% | 85.7% |
| Operating Margin | 19.4% | 8.6% |
| Net Margin | 13.3% | 0.9% |
| Revenue YoY | -1.8% | 23.7% |
| Net Profit YoY | -35.7% | -88.5% |
| EPS (diluted) | $0.51 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $185.2M | ||
| Q3 25 | $191.8M | $169.1M | ||
| Q2 25 | $174.4M | $154.7M | ||
| Q1 25 | $170.5M | $125.2M | ||
| Q4 24 | $186.5M | $149.7M | ||
| Q3 24 | $191.2M | $141.5M | ||
| Q2 24 | $182.4M | $126.7M | ||
| Q1 24 | $171.8M | $110.4M |
| Q4 25 | $24.4M | $1.7M | ||
| Q3 25 | $17.4M | $17.3M | ||
| Q2 25 | $31.0M | $-24.4M | ||
| Q1 25 | $25.3M | $-21.7M | ||
| Q4 24 | $38.0M | $14.7M | ||
| Q3 24 | $40.4M | $-6.7M | ||
| Q2 24 | $37.9M | $-15.7M | ||
| Q1 24 | $43.2M | $-48.4M |
| Q4 25 | 46.8% | 85.7% | ||
| Q3 25 | 51.4% | 88.5% | ||
| Q2 25 | 49.6% | 90.2% | ||
| Q1 25 | 50.0% | 90.7% | ||
| Q4 24 | 46.5% | 90.1% | ||
| Q3 24 | 53.3% | 90.6% | ||
| Q2 24 | 52.2% | 91.1% | ||
| Q1 24 | 52.4% | 87.7% |
| Q4 25 | 19.4% | 8.6% | ||
| Q3 25 | 13.2% | 20.3% | ||
| Q2 25 | 24.2% | -6.1% | ||
| Q1 25 | 21.9% | -6.3% | ||
| Q4 24 | 24.2% | 10.7% | ||
| Q3 24 | 29.8% | 15.3% | ||
| Q2 24 | 30.3% | 11.8% | ||
| Q1 24 | 27.9% | -25.1% |
| Q4 25 | 13.3% | 0.9% | ||
| Q3 25 | 9.0% | 10.2% | ||
| Q2 25 | 17.8% | -15.8% | ||
| Q1 25 | 14.8% | -17.3% | ||
| Q4 24 | 20.4% | 9.8% | ||
| Q3 24 | 21.1% | -4.8% | ||
| Q2 24 | 20.8% | -12.4% | ||
| Q1 24 | 25.1% | -43.9% |
| Q4 25 | $0.51 | $0.00 | ||
| Q3 25 | $0.37 | $0.06 | ||
| Q2 25 | $0.64 | $-0.08 | ||
| Q1 25 | $0.51 | $-0.07 | ||
| Q4 24 | $0.74 | $0.05 | ||
| Q3 24 | $0.78 | $-0.02 | ||
| Q2 24 | $0.73 | $-0.05 | ||
| Q1 24 | $0.81 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $293.5M |
| Total DebtLower is stronger | $608.7M | $392.7M |
| Stockholders' EquityBook value | $788.8M | $274.2M |
| Total Assets | $1.6B | $949.9M |
| Debt / EquityLower = less leverage | 0.77× | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $293.5M | ||
| Q3 25 | $276.2M | $263.8M | ||
| Q2 25 | $231.8M | $231.0M | ||
| Q1 25 | $236.9M | $250.6M | ||
| Q4 24 | $221.6M | $249.9M | ||
| Q3 24 | $250.5M | $249.8M | ||
| Q2 24 | $217.8M | $260.1M | ||
| Q1 24 | $289.6M | $239.6M |
| Q4 25 | $608.7M | $392.7M | ||
| Q3 25 | $608.6M | $392.0M | ||
| Q2 25 | $607.7M | $391.3M | ||
| Q1 25 | $603.9M | $390.7M | ||
| Q4 24 | $601.6M | $390.1M | ||
| Q3 24 | $596.4M | $389.5M | ||
| Q2 24 | $586.9M | $388.9M | ||
| Q1 24 | $594.0M | $388.4M |
| Q4 25 | $788.8M | $274.2M | ||
| Q3 25 | $776.7M | $230.4M | ||
| Q2 25 | $757.5M | $204.3M | ||
| Q1 25 | $751.3M | $193.6M | ||
| Q4 24 | $732.3M | $194.0M | ||
| Q3 24 | $727.7M | $178.8M | ||
| Q2 24 | $713.3M | $132.5M | ||
| Q1 24 | $672.4M | $130.7M |
| Q4 25 | $1.6B | $949.9M | ||
| Q3 25 | $1.7B | $868.8M | ||
| Q2 25 | $1.6B | $815.3M | ||
| Q1 25 | $1.6B | $789.8M | ||
| Q4 24 | $1.6B | $785.0M | ||
| Q3 24 | $1.5B | $786.6M | ||
| Q2 24 | $1.5B | $749.5M | ||
| Q1 24 | $1.6B | $721.8M |
| Q4 25 | 0.77× | 1.43× | ||
| Q3 25 | 0.78× | 1.70× | ||
| Q2 25 | 0.80× | 1.92× | ||
| Q1 25 | 0.80× | 2.02× | ||
| Q4 24 | 0.82× | 2.01× | ||
| Q3 24 | 0.82× | 2.18× | ||
| Q2 24 | 0.82× | 2.93× | ||
| Q1 24 | 0.88× | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $16.3M |
| Free Cash FlowOCF − Capex | $24.6M | $16.0M |
| FCF MarginFCF / Revenue | 13.4% | 8.6% |
| Capex IntensityCapex / Revenue | 4.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.35× | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $16.3M | ||
| Q3 25 | $52.6M | $35.7M | ||
| Q2 25 | $35.6M | $-26.5M | ||
| Q1 25 | $35.1M | $7.8M | ||
| Q4 24 | $29.0M | $-3.9M | ||
| Q3 24 | $60.0M | $-23.0M | ||
| Q2 24 | $69.1M | $22.7M | ||
| Q1 24 | $55.3M | $-29.7M |
| Q4 25 | $24.6M | $16.0M | ||
| Q3 25 | $47.2M | $35.3M | ||
| Q2 25 | $25.0M | $-28.9M | ||
| Q1 25 | $24.4M | $7.5M | ||
| Q4 24 | $16.6M | $-4.2M | ||
| Q3 24 | $46.2M | $-23.3M | ||
| Q2 24 | $63.1M | $21.6M | ||
| Q1 24 | $46.5M | $-31.5M |
| Q4 25 | 13.4% | 8.6% | ||
| Q3 25 | 24.6% | 20.9% | ||
| Q2 25 | 14.3% | -18.7% | ||
| Q1 25 | 14.3% | 6.0% | ||
| Q4 24 | 8.9% | -2.8% | ||
| Q3 24 | 24.1% | -16.5% | ||
| Q2 24 | 34.6% | 17.0% | ||
| Q1 24 | 27.1% | -28.5% |
| Q4 25 | 4.5% | 0.2% | ||
| Q3 25 | 2.8% | 0.2% | ||
| Q2 25 | 6.1% | 1.6% | ||
| Q1 25 | 6.3% | 0.2% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.3% | ||
| Q2 24 | 3.3% | 0.9% | ||
| Q1 24 | 5.1% | 1.6% |
| Q4 25 | 1.35× | 9.62× | ||
| Q3 25 | 3.03× | 2.06× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | -0.27× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
